AIA Group Ltd trimmed its holdings in shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 69.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 43,857 shares of the company's stock after selling 101,293 shares during the period. AIA Group Ltd's holdings in Dr. Reddy's Laboratories were worth $578,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of the business. Invesco Ltd. lifted its stake in Dr. Reddy's Laboratories by 15.7% during the 1st quarter. Invesco Ltd. now owns 235,435 shares of the company's stock valued at $3,105,000 after acquiring an additional 32,031 shares during the period. National Bank of Canada FI lifted its stake in Dr. Reddy's Laboratories by 331.2% during the 1st quarter. National Bank of Canada FI now owns 71,000 shares of the company's stock valued at $936,000 after acquiring an additional 54,536 shares during the period. CenterBook Partners LP acquired a new position in shares of Dr. Reddy's Laboratories in the 1st quarter valued at $258,000. Vanguard Group Inc. lifted its stake in shares of Dr. Reddy's Laboratories by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 5,002,642 shares of the company's stock valued at $65,985,000 after purchasing an additional 106,457 shares during the period. Finally, Costello Asset Management INC acquired a new position in shares of Dr. Reddy's Laboratories in the 1st quarter valued at $26,000. 3.85% of the stock is currently owned by institutional investors and hedge funds.
Dr. Reddy's Laboratories Price Performance
NYSE:RDY traded up $0.11 during trading hours on Friday, reaching $14.22. 650,994 shares of the company were exchanged, compared to its average volume of 1,502,940. Dr. Reddy's Laboratories Ltd has a twelve month low of $12.26 and a twelve month high of $16.85. The firm has a market cap of $11.87 billion, a PE ratio of 21.55, a price-to-earnings-growth ratio of 5.72 and a beta of 0.29. The stock's 50-day moving average is $14.75 and its 200-day moving average is $14.01. The company has a current ratio of 1.89, a quick ratio of 1.36 and a debt-to-equity ratio of 0.01.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its earnings results on Wednesday, July 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.02. Dr. Reddy's Laboratories had a net margin of 16.99% and a return on equity of 17.25%. The business had revenue of $988.82 million during the quarter, compared to analyst estimates of $88.27 billion. On average, sell-side analysts anticipate that Dr. Reddy's Laboratories Ltd will post 0.8 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the stock. Hsbc Global Res upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. Wall Street Zen upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, HSBC upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating and boosted their target price for the company from $14.44 to $16.90 in a research note on Thursday, June 5th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $16.95.
Check Out Our Latest Analysis on Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Company Profile
(
Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Featured Articles
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
